Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
RNA Vaccines Pipeline Analysis Market: By Clinical Trial Phase, By Application, and Geography
RNA Vaccines Pipeline Analysis Market: By Clinical Trial Phase, By Application, and Geography
RNA Vaccines Pipeline Analysis Market size was valued at US$ 36.43 billion in 2023 and is expected to reach US$ 57.89 billion by 2030, at a significant CAGR of 13.5% from 2023-2029. Due to increase in prevalence of chronic diseases such as cancer and cardiovascular diseases, the surge in many biopharmaceutical and biotechnology industries, the rise in funding for the development of RNA vaccines from public and private sectors, promising pipeline drugs, and wide range of applications with RNA vaccines are the major factors that are driving the growth of the global RNA vaccines market over the forecast timeframe. The report studies global RNA vaccines dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market.
In addition, the global RNA vaccines market report includes human demographics; regulatory scenario, and competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global RNA vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product Opportunities). Key stakeholders of the global RNA vaccines market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global RNA vaccines products.
Study Period
2024-2030Base Year
2023CAGR
13.5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA vaccines market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi vaccines, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA vaccines market over the forecast years.
North America accounted for larger revenue share in global RNA vaccines market with significant CAGR. Increase in prevalence of cancer, cardiovascular, and other chronic diseases in U.S. and Canada, rise in R&D activities for the development of RNA vaccines, and promising pipeline products and product approval by FDA are anticipated to propel the market. Europe RNA vaccines market projected to grow at significant rate owing to increase in research and development on newer RNA vaccines in the market for chronic diseases, increase in number of biopharmaceutical and biotechnology industries, and increase in healthcare expenditure are expected to enhance the market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 36.43 billion |
|
Market Size in 2030 |
US$ 57.89 billion |
|
Market CAGR |
13.5% |
|
By Clinical Trial Phase |
|
|
By Application |
|
|
By Region |
|
Download Free Sample Report
The rna vaccines pipeline analysis size was valued at US$ 36.43 billion in 2023
The RNA Vaccines Pipeline Analysis Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The RNA Vaccines Pipeline Analysis Market key players Moderna, Inc., CureVac AG, BioNTech AG, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, miRagen Vaccines, Inc., GeneOne Life Science
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.